Our study findings provide clinical evidence regarding ACE-I and ARB therapy during the COVID-19 pandemic, in response to calls made by several medical societies to clarify the theoretical risk of harm.9 Our study supports their recommendation in continuing ACE-I/ARB therapy for indications where these agents are shown to be beneficial, such as heart failure, hypertension, and ischemic heart disease.9 Uniquely, the prospective design of our study allowed us to identify COVID-19 patients presenting to the hospital on active ACE-I and ARB therapy. The gene discussed is ACE; the disease is COVID-19.